FAFarzana Alam

Farzana Alam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farzana Alam has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Taslim A. Al-Hilal

    Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea

    2 shared publications
  • Youngro Byun

    Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

    2 shared publications
  • Donghyun Seo

    Department of Biomedical Engineering, Computer and Biomedical Engineering, Medical Industry Techno Tower R307, Yonsei University, Wonju, Gangwon 220-710, South Korea

    1 shared publication
  • Fakhrul Ahsan

    Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA; Veterans Affairs Northern California Health Care System, Martinez, CA 94553, USA

    1 shared publication
  • Foyez Mahmud

    Division of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA

    1 shared publication
  • Han Sung Kim

    Department of Biomedical Engineering, Computer and Biomedical Engineering, Medical Industry Techno Tower R307, Yonsei University, Wonju, Gangwon 220-710, South Korea

    1 shared publication

Latest Publications

  • Open Access

    Targeting prion-like protein doppel selectively suppresses tumor angiogenesis

    by Taslim A. Al-Hilal, Seung Woo Chung, Jeong Uk Choi, Farzana Alam, Jooho Park, Seong Who Kim, Sang Yoon Kim, Fakhrul Ahsan, In-San Kim, Youngro Byun

    Controlled and site-specific regulation of growth factor signaling remains a major challenge for current antiangiogenic therapies, as these antiangiogenic agents target normal vasculature as well tumor vasculature. In this article, we identified the prion-like protein doppel as a potential therapeutic target for tumor angiogenesis. We investigated the interactions between doppel and VEGFR2 and evaluated whether blocking the doppel/VEGFR2 axis suppresses the process of angiogenesis. We discovered that tumor endothelial cells (TECs), but not normal ECs, express doppel; tumors from patients and mouse xenografts expressed doppel in their vasculatures. Induced doppel overexpression in ECs enhanced vascularization, whereas doppel constitutively colocalized and complexed with VEGFR2 in TECs. Doppel inhibition depleted VEGFR2 from the cell membrane, subsequently inducing the internalization and degradation of VEGFR2 and thereby attenuating VEGFR2 signaling. We also synthesized an orally active glycosaminoglycan (LHbisD4) that specifically binds with doppel. We determined that LHbisD4 concentrates over the tumor site and that genetic loss of doppel in TECs decreases LHbisD4 binding and targeting both in vitro and in vivo. Moreover, LHbisD4 eliminated VEGFR2 from the cell membrane, prevented VEGF binding in TECs, and suppressed tumor growth. Together, our results demonstrate that blocking doppel can control VEGF signaling in TECs and selectively inhibit tumor angiogenesis.


  • Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid

    by Farzana Alam, Taslim A. Al-Hilal, Seung Woo Chung, Donghyun Seo, Foyez Mahmud, Han Sung Kim, Sang Yoon Kim, Youngro Byun